Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
Status:
Terminated
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label extension protocol that will provide necessary data on the safety,
tolerability, pharmacokinetics and efficacy of STX209 among subjects with ASD.